Theriva Biologics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
TOVX$0.17-0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands except share and par value amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · December 31, · December 31, | ||||||
| · · 2024 · · 2023 | ||||||
| Assets · · | ||||||
| · · | ||||||
| Current Assets · · | ||||||
| Cash and cash equivalents | | $11,609 | | $23,177 | ||
| Tax credit receivable | | | 3,228 | | | 1,812 |
| Prepaid expenses and other current assets | | 1,444 | | 2,414 | ||
| Total Current Assets | | 16,281 | | 27,403 | ||
| | | | | |||
| Non-Current Assets | | | | | ||
| Property and equipment, net | | 270 | | 422 | ||
| Restricted cash | | | 96 | | | 102 |
| Right of use asset | | | 1,272 | | | 1,759 |
| In-process research and development | | 17,358 | | 19,755 | ||
| Goodwill | | — | | 5,700 | ||
| Deposits and other assets | | | 75 | | | 78 |
| Total Assets | | $35,352 | | $55,219 | ||
| Liabilities and Stockholders’ Equity | | | | |||
| | | | ||||
| Current Liabilities: | | | ||||
| Accounts payable | | $859 | | $770 | ||
| Accrued expenses | | 3,368 | | 2,995 | ||
| Accrued employee benefits | | | 1,144 | | | 1,517 |
| Deferred research and development tax credit-current portion | | | 1,614 | | | 906 |
| Loans payable-current | | | 61 | | | 63 |
| Operating lease liability-current portion | | | 539 | | | 487 |
| Total Current Liabilities | | 7,585 | | 6,738 | ||
| | | | | | | |
| Non-current Liabilities | | | | | | |
| Non-current contingent consideration | | | 6,973 | | | 6,274 |
| Loan Payable - non-current | | | 92 | | | 162 |
| Non-current deferred research and development tax credit | | | 762 | | | 906 |
| Non-current operating lease liability | | | 873 | | | 1,442 |
| Total Liabilities | | 16,285 | | 15,522 | ||
| | | | | | | |
| Commitments and Contingencies | | — | | — | ||
| Temporary Equity; 10,000,000 authorized | | | | | | |
| Series C convertible preferred stock, $0.001 par value; 10,000,000 authorized; 0 issued and outstanding at December 31, 2024, and 275,000 issued and outstanding at December 31, 2023 | | — | | 2,006 | ||
| Series D convertible preferred stock, $0.001 par value; 10,000,000 authorized; 0 issued and outstanding at December 31, 2024 and 100,000 issued and outstanding at December 31, 2023 | | | — | | | 728 |
| Stockholders’ Equity: | | | ||||
| Common stock, $0.001 par value; 350,000,000 shares authorized, 2,811,258 issued and 2,782,449 outstanding at December 31, 2024 and 715,028 issued and 686,219 outstanding at December 31, 2023 | | 3 | | 1 | ||
| Additional paid-in capital | | 355,501 | | 346,536 | ||
| Treasury stock at cost, 28,809 shares at December 31, 2024 and at December 31, 2023 | | | (288) | | | (288) |
| Accumulated other comprehensive (loss) income | | | (1,178) | | | 32 |
| Accumulated deficit | | (334,971) | | (309,318) | ||
| Total Stockholders‘ Equity | | | 19,067 | | | 36,963 |
| | | | | | | |
| Total Liabilities and Stockholders’ Equity | | $35,352 | | $55,219 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.